CLICK HERE if you are having a problem viewing the photos on a mobile deviceMIAMI — This is the kind of report card you take from the mailbox before your parents find it.The Raiders blew a third consecutive second-half lead, this time a 10-point advantage late in the third quarter than ended in an eight-point loss.Dolphins 28, Raiders 20 was the final score, but the numbers alone hardly tell the story of another Oakland breakdown that has Jon Gruden’s return reaching dangerous levels before …
What it Takes to Build a Highly Secure FinTech … Role of Mobile App Analytics In-App Engagement The Rise and Rise of Mobile Payment Technology Why IoT Apps are Eating Device Interfaces mike melanson So, should you stop broadcasting your location? I vote no. (And not because I want to stalk you, I swear.) I share my location all the time and for a number of reasons. It enables random and serendipitous connections to occur. I can look back and have all sorts of contextual information as I weave my way through the world. I can plug it all in to services like MemoLane and get a time-ordered snapshot of my own life, as I share it online. And in turn, it gets fed through algorithms and stuffed into features like Foursquare’s latest recommendation service, which looks at where I’ve been and suggests where I may want to go next. And that’s just the first step for what can be done with all of this location information. I also get second hand value from all this public location sharing. I see people’s check-ins on Twitter and can figure out that the coffee shop down the street is the place to be. Tweets can help with a host of scenarios, from public health issues to mysterious explosions in Portland.Of course, I may be a bit overzealous in my location sharing. It’s on, by default, for everything – pictures, check-in services (which are public) and Tweets. Go ahead – download Creepy and enter @rwwmike and you’ll see my recent trips to Palm Springs, CA and Austin, TX. You’ll see my bike ride across town to Golden Gate Park. You’ll see snapshots of food and beer and bikes. This isn’t for everyone. If you have bad relationships with your exes or lawyers coming after you for bills, you might not want to live so publicly. And are we that far off from insurance companies gathering check-in information and using it to calculate your premiums? But that’s what Creepy is about, right? It’s saying “Look, you’re sharing your life on the Internet and really, everyone can see.” The question is, do you care? (And perhaps, far more importantly, should you care?)Creepy is available for Windows and Linux with a Mac version on the way. Tags:#Location#mobile#news#privacy#web Related Posts You might want to file this under the “perhaps this was obvious, but we needed another app to show us” category, but if you check in, Tweet your location and otherwise publicly broadcast your GPS coordinates for all the world to see on the Internet, other people can see where you are.Creepy is a desktop app for Windows and Linux and it’s a stalker’s dream come true. The big question, though, is should you stop sharing? And is it really all that creepy?Last year, all the talk was about PleaseRobMe, a website that simply showed where people were checked in. It did nothing more than a Twitter search for the Foursquare domain, but it brought to attention the idea that whenever you publicly broadcast your location, you also publicly broadcast your absence from home. You know, the place with the valuables.Creepy takes this idea a step further. It takes a couple minutes to gather all the data – which it searches for according to Twitter or Flickr username – before showing a very detailed map of every Tweet, check-in and geo-tagged picture that person has posted to the Internet for months on end. And depending on how a particular piece of information was sent, such as from a smartphone with an accurate GPS signal, the results can be, well…creepy. We’re talking “Yep, I was next to that oak tree in the park when I took that picture” creepy.
klint finley Tags:#APIs#hack How to Write a Welcome Email to New Employees? Related Posts Why You Love Online Quizzes 7 Types of Video that will Make a Massive Impac… Growing Phone Scams: 5 Tips To Avoid Kassi is a service that enables users to share items, rides, etc. within a community. It’s similar to several other services, such as NeighborGoods, Share Some Sugar and Freecycle. But with so many sharing sites, it’s hard to figure out where to turn. If I wanted to borrow a power drill in Portland, I’d need to search each of these sites individually. In a blog post at Sharable Kassi co-founder Juho Makkonen, proposed a common API that would enable users to search multiple sharing sites at once.“We would have to define an ontology that maps all the resources that can be shared (stuff, skills, space) and their subtypes and properties related to them,” he writes.Makkonen suggests that a site could use the common API to show search results from another site. “For example, if you were searching for a certain tool from NeighborGoods and did not find it, the search would then return results from Share Some Sugar and Freecycle.”Makkonen compares the idea to OpenSocial, but perhaps the Google Product Search data feed is a better model.Either way, as Makkonen points out, it’s not a perfect idea:When actually borrowing the item, the users would still need to sign up for those services. They would not be able to take their data from the original service with them. This data would include feedback received from other users and other information that is vital to facilitate sharing. A person with an excellent reputation as a frequent lender and a trustworthy borrower in NeighborGoods would become a suspicious newbie in Share Some Sugar.Makkonen suggests a distributed data storage system silimar to Diaspora could be used.What do you think – would this be helpful? Anyone already hacking away on something like this?
If you’re looking for the comments section, it has moved to our forum, The Chamber. You can go there to comment and holler about these articles, specifically in these threads. You can register for a free account right here and will need one to comment.If you’re wondering why we decided to do this, we wrote about that here. Thank you and cheers! Oklahoma State has one of the nation’s toughest schedules the rest of the way (USATSI)First and foremost, I should start by saying last weekend was pure insanity in college football. Big games, upsets, goal posts being torn down by massive crowds of Red Bull infused students… it was amazing.As for myself, I watched everything unfold with a group of friends I was visiting in Dallas. There’s really no substitute for watching big games in unfamiliar territories with fans of different teams.As you can imagine, the bar I was in/the state of Texas was pretty stoked when TCU pulled off the upset against OU. As a lifelong Okie, I should probably be less excited when the Sooners lose…but I was right there celebrating with strangers in Horned Frog t-shirts. It was during this activity that I was shaken to my core.At a table across the bar sat an older couple—probably both in their 60s, just taking in the excitement of a massive win. I approached this seemingly harmless duo with a smile on my face, excitedly telling them, “I went to Oklahoma State and I just want to say thank you for what just happened!” I was sincere in my appreciation, yet entirely unprepared for what followed.Without skipping a beat, the older gentlemen looked me in the eye and said, “Talk to me in two weeks and let’s see how you feel about us then.”I’m serious. He said that to me.I pride myself on my wit, okay? I’m typically ready for just about anything. But in this moment, in a random bar in Dallas, an old man in a purple shirt caught me completely off guard and ruined me. Took me to the old school and gave me an education. I returned to Oklahoma a broken man.But with his advice in mind, I began thinking about the seven games left on our schedule and decided to rank them based on the expected difficulty level.While I only wish I could revisit that situation (I’ve come up with 8,348 comebacks I should have said), the only level of revenge I can have here is knowing I’m not most worried about TCU.So take that.7. Kansas: This weekend at KansasKansas is 2-3 so far and strikes about as much fear into my heart as a kitten. I refuse to fear a team with Montell Cozart at QB. (Don’t make me regret such a strong stance, Cowboys)6: Texas: Nov. 15 at BPSVince Young’s not walking through that door. Colt McCoy’s not walking through that door. Mack Brown’s not walking through that door…5. West Virginia: Oct. 25 at BPSThis is clearly one of those games we should start worrying about, as West Virginia played OU and Alabama incredibly well. Really just glad this game is at home, and hopefully the team is still upset about last season.Because I am.4. Kansas State: Nov. 1 at Kansas StateWe’ve jumped them in the polls, but this is a terrifying game to play in Manhattan. Looked all over for a silver lining…luckily found this one: They only beat Iowa State by four points. Take what you can get.3. TCU: Oct. 18 at TCUI don’t know if I actually fear TCU more than K-State, or if the old man is still in my head. Regardless, this is a top 10 team and Trevone Boykin is apparently the real deal. Worried about what he can do with his feet against the Cowboy defense.2. Baylor: Nov. 22 at BaylorThings I don’t want to do: Go to the dentist, go grocery shopping, go to Waco to play the Bears. Something tells me they’re still upset about last season…but last season gives me hope, as well.1. OU: Dec. 6 at OUI get that OU lost to TCU and now everyone knows it’s possible…but this is a really good OU football team. To make matters worse, we have to travel to Norman to attempt the upset bid.I’m putting my eggs in the “Have Boone Pickens offer Katy Perry a large amount of money to ruin Trevor Knight’s life” basket. But we could also beat them straight up, sure.That works too.Totally Tickets is your source for Oklahoma State football tickets.
Twitter/@theACCDNMidway through the second half of Wednesday night’s 72-58 home win over Syracuse, the Louisville Cardinals were doing whatever they wanted on offense. The dominant display was heavily featured on SportsCenter this morning, where the Cardinals had three of the Top 10 plays of the day.First up, at No. 7, this beautiful behind-the-back assist by Chinanu Onuaku.Nanu droppin’ dimes. pic.twitter.com/7MFnoY0qRb— LouisvilleSportsLive (@LvilleSprtsLive) February 18, 2016Next, at No. 4, another Onuaku assist—this time to Jaylen Johnson for a powerful alley-oop.It’s like Louisville found a “if you make the other team cry they have to let you play in the tournament” loophole pic.twitter.com/m4kMWmXva4— Mike Rutherford (@CardChronicle) February 18, 2016And finally, Louisville took home the top play, with this ferocious alley-oop from Damion Lee to Donovan Mitchell.If you look close enough, you can see a smile on Donovan Mitchell’s face as he slams this one home for @GoCards!https://t.co/xlTSYEXZ08— ACC Digital Network (@theACCDN) February 18, 2016That one was just mean. Mitchell liked it so much, he made it the header photo for his Twitter profile. It’s been a rough few weeks for the Cardinals. Last night’s big win had to be pretty cathartic.
[dropcap]W[/dropcap]elcome to Starters Orders. Our daily midday update from the trading room at Star Sports with our key market movers for the day across all sports.Tuesday 28 February HORSE RACINGCLICK HERE FOR OUR CHELTENHAM 2017 ANTEPOST PRICES3.00 LingfieldSennockian Star 7/2 > 5/23.10 TowcesterToby Lerone 7/2 > 5/24.00Pinwood 7/2 > 5/2 Light Of Air 7/1 > 9/24.40 LeicesterThe Highlander 6/5 > 4/5LIVE FOOTBALLScottish Premiership19:45 BT Sport 1 / BT Sport 1 HD6/1 Hamilton Academical 1/2 Aberdeen 3/1 DRAWChampionship19:45 Sky Sports 1 / Sky Sports 1 HD6/4 Brighton & Hove Albion 21/10 Newcastle United 11/5 DRAWBET WITH STAR SPORTS 08000 521 321
low risk (pathologic tumour size [pT] < 2cm and N0), accounting for 37.5% of patients intermediate risk (pT < 2cm and any N category), accounting for 51.9% high risk (pT > 2cm and N4+), accounting for 10.5% of the patient population. Results showed that patients with low and intermediate risk had similar five-year DFS with a nine-week course of trastuzumab (88%) as with one year (89%; hazard ratio 1.02, 95% confidence interval [CI] 0.78-1.33) but their risk of cardiac events was nearly three times lower (4.5% vs 12.8%, relative risk 2.88 95% CI 1.85-4.47). Women at low and intermediate risk of relapse accounted for 89% of patients in the study.”The study was underpowered because of difficulties in recruiting patients in a reasonable time so non-inferiority could not be claimed based on the results,” said lead author Pierfranco Conte, Professor of Oncology at the University of Padua and Director of the Division of Medical Oncology at the Instituto Oncologico Veneto, Padua, Italy. He added: “Based on our data, one year trastuzumab remains the standard treatment for women with HER2-positive early breast cancer,”However, Conte added: “Physicians can stop trastuzumab before one year in patients who develop a cardiac event during treatment without compromising efficacy and can consider shorter-duration trastuzumab treatment in patients at risk of cardiac toxicity and a low or intermediate risk of breast cancer relapse.” He suggested that consideration of shorter-duration trastuzumab may also facilitate access to patients who cannot afford a longer course.Commenting on the study for ESMO, Prof. Nadia Harbeck, Head of the Breast Center, University of Munich, said: “The results of this analysis showed that patients with a high tumor load definitely derive substantial benefit from longer duration trastuzumab.”She added: “The results may impact on clinical decision-making, although it is an exploratory analysis of a negative trial so does not meet the criteria to be practice changing. I think it will influence clinicians and patients in that if patients cannot complete one year of trastuzumab, those patients with low tumour burden can feel reassured that they have not lost out on efficacy.”Six-month course of trastuzumab saves nearly £10,000 per patientA second study showed that a six-month course of adjuvant trastuzumab was cost-effective compared to 12 months, giving an average cost saving of nearly £10 000 (Euros 11,300) per patient with no evidence of detriment to quality of life (2).Related StoriesBacteria in the birth canal linked to lower risk of ovarian cancerAI-enabled device detects if targeted chemotherapy is workingNew protein target for deadly ovarian cancerResearchers analyzed the cost-effectiveness of a six-month course of adjuvant trastuzumab compared to the standard 12-month course in patients with HER2 positive early breast cancer taking part in the PERSEPHONE trial. This is the largest phase 3 randomised trial to compare six months with 12 months of trastuzumab and demonstrated non-inferiority of reduced-duration trastuzumab (5).The new study analyzed health service activity and costs in addition to quality of life in 4009 patients who were disease free at six months; 250 were excluded due to lack of data. In a landmark analysis six months into treatment the researchers estimated the cost-effectiveness of six months of trastuzumab compared to a 12-month course of trastuzumab from the perspective of the health and social care sector over two years of follow-up.Results showed the average costs for an individual patient treated with trastuzumab for six months were £2,538.64 (95% confidence interval [CI] £2,383.38-£2,700.72) compared to average costs per patient of £12,333.83 (95% CI £12,098.58-£12,562.27) in those treated with trastuzumab for 12 months.Treating for six months gave an average cost saving of £9,793.25 (95% CI £9,515.86-£10,071.64) per patient. Trastuzumab treatment and administration accounted for the vast majority of this cost saving, with the remainder arising from cardiac assessment and treatment costs and inpatient days.The average Quality Adjusted Life Years (QALYs) for an individual in the 6-month arm and 12-month arm were 1.146 (95% CI: 1.131 – 1.161) and 1.128 (95% CI: 1.113 – 1.144), respectively, giving an average QALY difference of 0.018 (95% CI: – 0.003 – 0.039). Thus the 6-month treatment arm dominated, with a probability of being cost-effective of 100%.”A six-month duration of adjuvant trastuzumab with chemotherapy was found to be cost-effective compared with 12 months, which is currently the standard of care,” said lead author Claire Hulme, Professor of Health Economics at the Academic Unit of Health Economics, University of Leeds, Leeds, UK.She added: “The results, alongside the clinical effectiveness results demonstrating non-inferiority, are the first steps in the safe reduction of treatment for many women with HER-2 positive breast cancer. They present an opportunity for significant cost savings for health service providers.”Hulme acknowledged that a limitation of the study was that it was a landmark study, which meant the researchers looked only at a specific timepoint from six months into trastuzumab treatment. She said the research group intends to carry out further sensitivity analysis and to assess the financial costs of treatment to patients rather than only from the perspective of health service providers.Harbeck commented: “Showing that it was more economical to treat with six months of trastuzumab versus 12 months is an important contribution for global access to treatment.” But she added: “The subgroup analysis of PERSEPHONE could not exclude a benefit of one year trastuzumab in clinically relevant subgroups, so one year remains the standard duration. And we now have biosimilars, which could also help to increase access to treatment in countries where there is no general access.”Looking to the future, she said: “We should not do these trials assuming ‘one size fits all’ for the whole population but we should take into account patients’ individual responses to neoadjuvant anti-HER2 therapy and ask the question whether patients who have sufficient response may forgo further therapy.” She noted that recent research has also shown that high-risk patients benefit from two HER-2 antibodies, such as trastuzumab and pertuzumab, more than one. Source:https://www.esmo.org/ Reviewed by James Ives, M.Psych. (Editor)Oct 22 2018Women with HER2-positive early breast cancer with small tumors have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.A second study showed that a six-month course of adjuvant trastuzumab was cost-effective compared to 12 months, with an average cost saving of nearly £10,000 (Euros 11,300) per patient.Current guidelines recommend one year of anti-HER2 antibody therapy as part of standard adjuvant treatment for HER2-positive early breast cancer patients based on the duration of treatment used in pivotal registration trials. There is interest in whether a shorter course of trastuzumab could potentially achieve similar efficacy with lower risk of side-effects and costs.The Short-HER trial randomized 1254 HER2-positive early breast cancer patients to either nine weeks or one year’s treatment with trastuzumab, with both groups also receiving chemotherapy. Results after a median of six years’ follow-up showed the short course did not achieve non-inferiority but was associated with a reduction in the rate of severe cardiac toxicity.The researchers have now analyzed whether there are subgroups of patients where a shorter course of trastuzumab may be non-inferior to a longer course. Multivariate analysis showed that pathologic tumour size (pT) and nodal status (N) were independent prognostic factors for disease-free survival (DFS).They identified three prognostic groups:
Source:https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2018-11-06-study-shows-potential-to-develop-brain-tumour-liquid-biopsies Reviewed by James Ives, M.Psych. (Editor)Nov 7 2018Scientists are making strides in developing liquid biopsies for brain tumors by detecting tumor DNA in the fluid from around the brain and spine.Liquid biopsies are fluid samples from patients, for example from the blood or urine, which provide a less invasive way to monitor disease compared to tumor biopsies. A less intrusive test could be hugely beneficial for brain tumors where collecting samples can be difficult and risky for patients.Scientists at the Cancer Research UK Cambridge Institute analyzed cerebrospinal fluid (CSF) – which bathes the brain and spinal cord – in 13 patients with a type of brain tumor called a glioma. They detected tumor DNA in five (39%) of the patients and their findings are published in EMBO Molecular Medicine.Researchers used a cheap and widely available technique called shallow whole-genome sequencing to detect brain tumor DNA – they looked for large genetic changes, such as genes being duplicated or lost.Related StoriesMathematical model helps quantify metastatic cell behaviorStudy provides new insight into longitudinal decline in brain network integrity associated with agingWearing a hearing aid may mitigate dementia riskFor the first time, the researchers identified tumor DNA in the CSF by looking at the size of the DNA fragments, which are shorter than those from healthy cells. This provides another way to detect brain tumor DNA, potentially increasing the detection rate.In one patient, multiple tissue samples from their brain tumor were compared to their CSF. The genetic changes broadly matched, but the CSF contained changes that were missed in some of the tissue samples, suggesting that CSF samples could reflect the repertoire of genetic alterations found in brain tumors.Dr Florent Mouliere, co-first author, who conducted the work as a scientist at the Cancer Research UK Cambridge Institute, said: “Liquid biopsies are showing great promise for a number of cancer types, but tests for brain tumors have lagged behind due to the low levels of tumor DNA found in body fluids, in particular the blood.”Our work shows that a cheap, easily available technique can be used to analyse tumor DNA in cerebrospinal fluid. In the future, we envisage that this technique could be used to identify patients who may benefit from further tests that could help monitor their disease, opening up more tailored treatment approaches.”Around 11,400 people are diagnosed with brain tumors in the UK every year and only 14% of people will survive their disease for a decade or more. That’s why Cancer Research UK has made brain tumor research one of its priorities, spending around £25 million over the next five years.Professor Charles Swanton, Cancer Research UK’s Chief Clinician, said: “Survival for brain tumors remains low and there is an urgent need for research like this to identify strategies to better manage these complex diseases. This study lays important groundwork that brings the possibility of liquid biopsies for this hard to treat disease one step closer.”The researchers will now need to expand this work into larger numbers of patients and find out whether this approach could have applications in the clinic, such as indicating whether a patient’s treatment is working.”
New study considers a woman’s risk to develop one of four pelvic floor disorders based on childbirth delivery method. Credit: iStock We knew that these disorders are more common after childbirth, but now after following these women for 10 years, we have a good sense of how delivery mode impacts a woman’s risk of developing a pelvic floor disorder.”Victoria Handa, M.D., M.H.S., professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine and director of gynecology and obstetrics at Johns Hopkins Bayview Medical Center Dec 20 2018Decade-long study identifies women at highest risk for incontinenceResearch completed at Johns Hopkins and the Greater Baltimore Medical Center has demonstrated that vaginal childbirth substantially increases the probability a woman will develop a pelvic floor disorder later in life. Pelvic floor disorders, including urinary incontinence and uterine prolapse, afflict millions of women in the United States. However, until now little was known about who will develop these conditions and how they progress over time. In this week’s Journal of the American Medical Association, Johns Hopkins and Greater Baltimore Medical Center researchers report results of a 10-year study showing that some delivery modes, including spontaneous vaginal delivery, are associated with higher risk of some types of pelvic floor disorders. This study considered a woman’s risk of developing one of four pelvic floor disorders: stress urinary incontinence (urine leakage during with activities that increase abdominal pressure), overactive bladder (frequent and urgent urination), anal incontinence (involuntary loss of solid stool, liquid stool or gas) and pelvic organ prolapse (when the uterus and vaginal walls fall downward into the vagina, protruding beyond the vaginal opening when bearing down).The research team enrolled 1,528 women within five to 10 years of their first birth. These women were followed annually for up to nine years. Of the women, 778 delivered all of their children via cesarean birth, 565 had at least one spontaneous vaginal delivery and 185 had at least one delivery involving forceps or vacuum-assistance, also called operative vaginal delivery. The median age at enrollment was 38.3—the youngest study participant at enrollment was 22.7 years old and the oldest participant at the end of the study was age 61.7.Related StoriesLow maternal education linked to high risk of infant mortalityHistory of eating disorders associated with future depressive symptoms among mothersQueen’s researchers develop innovative rapid test to improve maternal health in developing countriesThe team collected information from the women at the time of enrollment, including date of first birth, age at first birth, body mass index, whether they had developed any pelvic floor disorder already, birth delivery mode, and genital hiatus size— the distance between the urethra and the posterior hymen. The team then collected information at follow-up visits—the cesarean birth group made 4,039 visits, the spontaneous vaginal delivery group made 2,817 visits and the operative vaginal delivery group made 948 visits. Some women already had developed pelvic floor disorders at the time of study enrollment while others developed the conditions over the course of the study.In all, the researchers found that cesarean delivery substantially reduced the risk of pelvic floor disorders, most notably pelvic organ prolapse, while operative delivery increased the risk. And for pelvic organ prolapse, the magnitude of these differences grew over time. For example, by 15 years after a first delivery, prolapse of the uterus or vaginal wall beyond the vaginal opening was seen in 9 percent (7–12 percent) of women who had delivered by cesarean, 30 percent (25–35 percent) who had at least one vaginal delivery and 45 percent (37–53 percent) of those who had at least one operative delivery. The researchers also found that a large percentage of new cases of urinary and bowel incontinence developed in the first five years after delivery, while pelvic organ prolapse tended to develop many more years after childbirth. A third discovery was that the genital hiatus size is significantly associated with all pelvic floor disorders but most significantly with pelvic organ prolapse. This suggests that the genital hiatus size is a marker that might identify women at high risk of developing pelvic floor disorders with aging. While this study was limited to one community hospital and might not accurately reflect populations nation- or world-wide, it is the first time we have been able to gather data over a significant period of time. These data help us understand which women might be at highest risk to develop these conditions. Ultimately this research will help us identify which women should be targeted for prevention strategies, and will hopefully improve our ability to deliver the right type of care to the right person.”Victoria Handa Source:https://www.hopkinsmedicine.org/news/newsroom/news-releases/delivery-method-associated-with-pelvic-floor-disorders-after-childbirth
Reviewed by James Ives, M.Psych. (Editor)Mar 27 2019The survival rate among extremely preterm babies has greatly improved in Sweden, a country that offers top-class neonatal care, a study led from Karolinska Institutet published in the esteemed journal JAMA reports.The researchers have analysed survival among Swedish babies born over 3.5 months prematurely in week 22-26 and compared the statistics from 2014-2016 to those from 2004-2007. All Swedish hospitals participated in the study, which included 2,205 women who had had complications during pregnancy leading to extremely preterm births.Between these two time periods, the stillbirth rate dropped from 30 to 23 per cent, while the survival rate rose from 70 to 77 per cent. Further, the higher survival was not achieved at the cost of more complications during the neonate period; on the contrary, the researchers observed a reduction in the number of brain and lung damage in the babies born between 2014 and 2016, while the number of other problems, such as eye and abdominal complications, remained unchanged.World class survival rate”Even if there are individual hospitals around the world that have been able to show similar results for selected patients, the survival of an entire population and for a whole country is world class,” says Mikael Norman, professor of paediatrics at the Department of Clinical Science, Intervention and Technology at Karolinska Institutet in Sweden and the researcher responsible for the study.By way of comparison, the survival rate for babies born in week 22-26 is around 50 per cent in the UK, France and the USA. And in many comparable countries, it is still rare for babies born in week 22-23 to survive.Greatest improvement in week 22Related StoriesStudy provides new insight into longitudinal decline in brain network integrity associated with agingNeural pathways explain the relationship between imagination and willingness to helpPosterior parietal cortex plays crucial role in making decisions, research showsThe Swedish study found the greatest improvement in survival in babies born in week 22 (from week 22+0 days to week 22+6 days) with birth weights of between 290 and 730 grams. Fifty-eight per cent of those from this group who were admitted to neonatal intensive care between the years 2014 and 2016 survived to at least one year-of-age.The results suggest that central care support initiatives are effective. In recent years, amendments to laws, guidelines and national recommendations have strengthened healthcare provision and the status of extremely preterm babies. Ultimately though, says Professor Norman, the results of the study are testimony to the capabilities of all the midwives, nurses and doctors who provide pregnant women and their babies the best available care 24 hours a day.”The profession and the authorities are both good at taking on board new knowledge and translating it into practice,” he says. “Even if certain problems related to adverse events and long-term complications amongst extremely preterm babies remain as vital areas for improvement, I really think that that Swedish neonatal care should fill us with a sense of pride and joy.”National collaborationLong-standing national collaboration between researchers and clinicians, and the establishment of the national neonatal quality register are other important contributors.”It has been essential to make available knowledge on how neonatal care has developed in Sweden,” says Professor Norman. Source:https://ki.se/en/news/sweden-leads-the-world-in-saving-extremely-preterm-babies